Fatemeh Behnia, M.D.

Associate Professor
Program Director, Nuclear Medicine Residency program
Nuclear Medicine

Biography

Dr. Behnia is a UW associate professor in the Division of Nuclear Medicine, Department of Radiology. She was trained as a radiologist in Iran. With more than 10 years of experience, she moved to the US in 2004, where she completed additional training in nuclear medicine at the University of Washington.

She is board certified in nuclear medicine and radiology. Her areas of interest are general nuclear medicine and oncology imaging. She has a passion for teaching recognized by multiple teaching awards since becoming a faculty member.

Recent Publications (via Semantic Scholar)

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
R. Lynch, R. Cassaday, Stephen D Smith, et al. - Published 2021 - THE LANCET. HAEMATOLOGY

A Phase I Trial of First-in-Human Alpha-Emitter Astatine-211-Labeled Anti-CD45 Antibody (211At-BC8-B10) in Combination with Fludarabine and TBI As Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome
B. Sandmaier, D. Wilbur, D. Hamlin, et al. - Published 2021

Clinical Benefit of Baseline Imaging in Merkel Cell Carcinoma: Analysis of 584 Patients.
Neha Singh, N. Alexander, K. Lachance, et al. - Published 2020 - JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.
S. Graf, R. Cassaday, K. Morris, et al. - Published 2020 - CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study
R. Lynch, R. Cassaday, Stephen D Smith, et al. - Published 2020